CTIX rocket launch.....pending Shorts will fry to

CTIX rocket launch.....pending

Shorts will fry today like fish in a pan

“We will be presenting the most recent data available from the clinical trials of Kevetrin hosted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “We are acutely aware that the oncology community and shareholders have a strong interest regarding schedule, maximum tolerated dose and potential efficacy of Kevetrin, given its uniqueness and potential. The laboratory informed us that additional samples were required for analysis of Kevetrin’s affect on biomarker p21, an early-stage indicator of efficacy. Those samples have been supplied by the hospital with more to be delivered as the trial progresses. We are hopeful that data will be available in time for ASCO.”